OLEIC ACID
Molecular Excipient
| Mwt. | LogP | HBD | HBA | PSA | RB | CSP3 |
|---|---|---|---|---|---|---|
| 281.0 | 4.8 | 0 | 2 | 40.0 | 15 | 0.83 |
- CAS
- 112801
- UNII
- 2UMI9U37CP
- SYNONYMS
-
- ZINC ID(s)
- Availability
- Present in 78 ZINC catalogs
Known Active Genes
This compound has been observed to have activity at 10μM or less against the following gene(s).
| Name | Description | Classification |
|---|---|---|
| FABP3 | Fatty acid-binding protein, heart | Auxiliary Transport Protein / Atp-Fabp |
| PPARG | Peroxisome proliferator-activated receptor gamma | Transcription Factor / Nr |
| FABP1 | Fatty acid-binding protein, liver | Unclassified / Unclassified |
| FABP5 | Fatty acid-binding protein, epidermal | Auxiliary Transport Protein / Atp-Fabp |
| FABP4 | Fatty acid-binding protein, adipocyte | Auxiliary Transport Protein / Atp-Fabp |
| PPARD | Peroxisome proliferator-activated receptor delta | Unclassified / Unclassified |
| FAAH | Fatty-acid amide hydrolase 1 | Enzyme / Enzyme-Other |
| PPARA | Peroxisome proliferator-activated receptor alpha | Transcription Factor / Nr |
Clinical Trials
This compound has been an intervention in the following clincial trials (per clinicaltrials.gov).
| Code | Date | Title | Phase | Status |
|---|---|---|---|---|
| NCT01661764 | 2012-09-01 | Fish Oil Supplementation, Nutrigenomics and Colorectal Cancer Prevention | Phase 2 | Recruiting |
| NCT01674946 | 2011-09-01 | Effect of Bile Acids on the Secretion of Satiation Peptides in Humans | Phase 1 | Completed |
| NCT00059254 | 2000-09-01 | Differential Metabolism of Dietary Fatty Acids | Phase 1 | Completed |
(Browse) Purchasable Analogs in ZINC
Functions of Oleic Acid
| Ctg - Component or coating |
| Misc - Miscellaneous |
Regulatory Status of Oleic Acid
| Gras - Generally recognized as safe. |
Dosages
| Route | Formulation | Per Unit Dose |
|---|---|---|
| Inhalation | Aerosol, Metered | 0.27% |
| Intravenous | Emulsion, Injection | 0.03% |
| Nasal | Aerosol, Metered | 0.13% |
| Oral | Aerosol, Metered | 4E-7% |
| Oral | Capsule, Soft Gelatin | 598.6MG |
| Oral | Inhalation | 0.0004% |
| Oral | Tablet, Coated | 0.72MG |
| Oral | Tablet, Extended Release | |
| Oral | Tablet, Film Coated | |
| Oral | Tablet, Repeat Action | 1.85MG |
| Oral | Tablet, Sustained Action | 2MG |
| Respiratory (Inhalation) | Aerosol, Metered | 0.0003% |
| Topical | Emulsion | |
| Topical | Emulsion, Cream | 25% |
| Topical | Gel | 2.5% |
| Topical | Solution | 7.4% |
| Transdermal | Film, Controlled Release | 22MG |
| Transdermal | Patch, Controlled Release | 5.51MG |